In the US, GLP-1 spending rose from $13 to $72 billion in just five years, making approval tough for patients without diabeteseven as data for arthritis risk and cardiovascular benefits grow
Morgan), but the geopolitical and logistical benefits are clear
Not all patients experience clinically meaningful improvements in cholesterol, and some may require additional lipid-lowering therapy regardless of weight loss
GLP-1 medications slow digestion, which may impair B12 absorption
However, unlike other health care or retail businesses, there are usually restrictions on what weight loss companies can say in their digital advertising and even where they can advertise
GLP-1 triggers insulin release: insulin tells your cells to take up glucose (sugar) from the blood to make energy